Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Drug PIC

Allergan Aesthetics’ JUVÉDERM VOLBELLA Wins NMPA Approval for Infraorbital Hollowing – Hyaluronic Acid Filler Expands China Label Beyond Lips

Fineline Cube Sep 11, 2026
Company Drug PIC

GSK’s Shingrix Wins Japan Approval for Prefilled Syringe Presentation – Recombinant Zoster Vaccine Gains Administration Flexibility

Fineline Cube Sep 11, 2026
Company Drug PIC

Hengrui’s Hetrombopag Wins China Approval for CTIT and Pediatric ITP – Oral TPO‑RA Expands Across Thrombocytopenia Indications

Fineline Cube Sep 11, 2026
Company Drug PIC

Roche’s Enspryng Granted FDA Priority Review for MOGAD – First IL‑6 Inhibitor Poised to Expand Beyond NMOSD

Fineline Cube Sep 11, 2026
Company Deals PIC

Boji Medical and Zhejiang Maiyata Sign Strategic Partnership – Leading China CRO Joins Microbiome Innovator to Advance Live Biotherapeutic Products

Fineline Cube Sep 11, 2026
Company Drug PIC

Allergan Aesthetics’ JUVÉDERM VOLBELLA Wins NMPA Approval for Infraorbital Hollowing – Hyaluronic Acid Filler Expands China Label Beyond Lips

Fineline Cube Sep 11, 2026
Policy / Regulatory

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

Fineline Cube Sep 11, 2026
Company Drug

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Fineline Cube Sep 11, 2026
Company Deals

Kingmed Diagnostics Partners with GenStar Biosolutions to Develop Auto-Antibody Immunofluorescence AI Software

Fineline Cube Apr 23, 2024

Kingmed Diagnostics, a leading independent medical laboratory based in Guangdong, has entered into a strategic...

Company Drug

GenScript’s Subsidiary Legend Biotech Expands EU Approval for CAR-T Therapy Carvykti

Fineline Cube Apr 23, 2024

China-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) has announced that its subsidiary,...

Company Drug

Ipsen’s Somatuline Receives First Prescription in China for GEP-NETs Treatment

Fineline Cube Apr 23, 2024

French biopharmaceutical company Ipsen (EPA: IPN; OTCMKTS: IPSEY) has announced that the first prescription of...

Company

Chongqing Zhifei Biological Reports 38.3% YOY Revenue Growth in 2023 Financial Results

Fineline Cube Apr 23, 2024

Chongqing Zhifei Biological Co., Ltd (SHE: 300122), a biopharmaceutical company based in China, has released...

Company Deals

Genrix Biopharmaceutical Partners with China Resource Medicine for Expanded Market Coverage

Fineline Cube Apr 23, 2024

Chongqing Genrix Biopharmaceutical Co., Ltd (SHA: 688443), a Chinese biopharmaceutical company, has entered into a...

Company Deals

Takeda and Astellas Join Forces with Sumitomo Mitsui to Launch Drug Discovery Joint Venture

Fineline Cube Apr 23, 2024

Japanese pharmaceutical giants Takeda (NYSE: TAK) and Astellas (TSE: 4503) have joined hands with compatriot...

Company

GenScript Biotech Corporation Reports 34.2% YOY Revenue Growth in 2023 Financial Results

Fineline Cube Apr 23, 2024

China-based GenScript Biotech Corporation (HKG: 1548) has announced its financial results for 2023, reporting revenues...

Company Deals

Bristol Myers Squibb Enhances CAR-T Manufacturing with Cellares Platform, Securing Exclusive Access

Fineline Cube Apr 23, 2024

Pharmaceutical giant Bristol Myers Squibb (BMS; NYSE: BMY) has secured a deal with Cellares, a...

Company

Zai Lab Ltd Appoints New Greater China CCO as Liang Yi Exits

Fineline Cube Apr 23, 2024

Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) has announced the appointment of Zhu Tong as...

Policy / Regulatory

China’s NMPA Introduces 12 Measures to Strengthen Drug Operation Administration

Fineline Cube Apr 23, 2024

The National Medical Products Administration (NMPA) has issued a notification with 12 measures aimed at...

Company Deals

MSD Strikes Deal with GV20 Therapeutics to Test Anti-PD-1 Combo in Solid Tumor Therapies

Fineline Cube Apr 22, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK), a global healthcare leader, has entered into a...

Company Drug

Jiangsu Hengrui’s SHR-A2102 Earns FDA Fast Track Status for Urothelial Carcinoma Treatment

Fineline Cube Apr 22, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a prominent pharmaceutical company in China, has announced...

Company Drug

Hengrui Pharmaceuticals Gets Green Light from NMPA for Two Anti-Cancer Drugs

Fineline Cube Apr 22, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced...

Company

Bayer CEO Joins German Chancellor on China Visit, Announces New Investments

Fineline Cube Apr 22, 2024

Bayer AG (ETR: BAYN, FRA: BAYN, OTCMKTS: BAYRY), a multinational pharmaceutical and life sciences company...

Company Drug

GSK’s Gepotidacin Shows Non-Inferior Efficacy in Phase III Gonorrhoea Tria

Fineline Cube Apr 22, 2024

GlaxoSmithKline (GSK; NYSE: GSK, LON: GSK), a leading UK pharmaceutical company, last week announced positive...

Company Drug

Joincare Pharmaceutical’s TG-1000 Shows Promise in Phase III Flu Treatment Trial

Fineline Cube Apr 22, 2024

Joincare Pharmaceutical Group Co., Ltd (SHA: 600380), a Chinese pharmaceutical company, has reportedly completed the...

Company Legal / IP

Kind Pharmaceuticals Resolves Trade Secrets Dispute with Fibrogen Amid HIF-PHI Pipeline Development

Fineline Cube Apr 22, 2024

Kind Pharmaceuticals LLC, a Sino-US pharmaceutical company, along with its Chinese affiliate Hangzhou Andao Pharmaceutical...

Company Drug

Roche’s Alecensa approved by FDA as First ALK Inhibitor for Adjuvant Treatment of NSCLC

Fineline Cube Apr 22, 2024

Roche Holding AG (SWX: ROG; OTCMKTS: RHHBY), a Swiss multinational healthcare company, announced last week...

Company Drug

Takeda Scores FDA Nod for Subcutaneous Vedolizumab to Treat Inflammatory Bowel Disease

Fineline Cube Apr 22, 2024

The US Food and Drug Administration (FDA) has granted Takeda Pharmaceutical Company Limited (NYSE: TAK),...

Company Deals

CareRay Digital Medical Invests $15 Million for Stake in X-Ray Detector Maker ISID

Fineline Cube Apr 22, 2024

CareRay Digital Medical Technology Co., Ltd, a leading medical technology company based in Jiangsu, has...

Posts pagination

1 … 425 426 427 … 719

Recent updates

  • Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption
  • BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis
  • Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China
  • China’s Seventh National VBP Round for Medical Consumables Concludes in Tianjin – 517 Digestive Intervention Products Selected Across 23 Categories
  • Ocumension’s OT‑301 NDA Accepted by China’s CDE – Dual‑Mechanism Glaucoma Therapy Advances Toward Approval in Open‑Angle Glaucoma and Ocular Hypertension
business cooperation with fineline tech

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

Company Drug

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Company Drug

Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China

Policy / Regulatory

China’s Seventh National VBP Round for Medical Consumables Concludes in Tianjin – 517 Digestive Intervention Products Selected Across 23 Categories

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.